Metformin Hydrochloride (SR) Glimepiride & Voglibose Tablets – Glanil MV 2.2 Tablets

Glanil MV 2.2 Tablets
Composition:- Glimepiride 2 mg + Metformin 500 mg + Voglibose 0.2 mg (Bilayered)

Glanil MV 2.2 Tablets is a Metformin Hydrochloride (SR) Glimepiride & Voglibose Tablets combination anti-diabetic formulation designed for effective management of Type 2 Diabetes Mellitus. Glimepiride helps stimulate insulin secretion; Metformin SR improves insulin sensitivity and reduces hepatic glucose production, while Voglibose delays carbohydrate absorption to control postprandial blood glucose spikes. The bilayered sustained-release formulation supports comprehensive glycemic control with improved patient compliance.

Marketed by: Wonne International Pvt. Ltd.

Key Points of Metformin Hydrochloride (SR) Glimepiride & Voglibose Tablets – Glanil MV 2.2 Tablets

• Comprehensive Triple Drug Therapy: Combines three anti-diabetic agents for effective fasting and post-meal glucose control.
• Controls Postprandial Sugar Spikes: Voglibose delays carbohydrate digestion and absorption to reduce post-meal hyperglycemia.
• Improves Insulin Utilization: Metformin SR supports better insulin sensitivity and reduces hepatic glucose production.
• Stimulates Insulin Secretion: Glimepiride enhances pancreatic insulin release for improved glycemic management.
• Bilayered Sustained-Release Advantage: Designed for prolonged therapeutic action and better patient convenience.

Can be Prescribed by:

• Diabetology
• Endocrinology
• General Medicine

Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.